Table 2.
Patient information for TrialNet whole blood RNA samples.
| AA- First Degree Relatives | |||||||
|---|---|---|---|---|---|---|---|
| ID | HLA (DRB1:DQA1:DQB1)* | Serum AA† | Age | Sex | Years to Onset | RNA RIN | |
| 1 | HLAa: 1401:0101:0503 HLAb: 1102:0501:0301 |
Negative | 13 | F | – | 8.1 | |
| 2 | HLAa: 1501:0102:0602 HLAb: 1301:0103:0603 |
Negative | 9 | F | – | 8.5 | |
| 3 | HLAa: 0701:0201:0202 HLAb: 0401:0301:0302 (DR4) |
Negative | 15 | M | – | 8.2 | |
| 4 | HLAa: 1201:0501:0301 HLAb: 1302:0501:0301 |
Negative | 18 | M | – | 7.8 | |
| 5 | HLAa: 0101:0101:0501 HLAb: 0102:0101:0501 |
Negative | 12 | F | – | 7.5 | |
| 6 | HLAa: 0401:0301:0302 (DR4) HLAb: 0701:0201:0202 |
Negative | 18 | F | – | 8.3 | |
| 7 | No data | Negative | 24 | F | – | 5.6 | |
| 8 | HLAa: 0701:0201:0202 HLAb: 0401:0301:0301 (DR4) |
Negative | 17 | M | - | 7.1 | |
| 9 | HLAa: 0701:0201:0202 HLAb: 0701:0201:0202 |
Negative | 7 | F | - | 8.1 | |
| 10 | HLAa: 0401:0301:0302 (DR4) HLAb: 0301:0501:0201(DR3) |
Negative | 12 | M | - | 7.8 | |
| 11 | HLAa: 0408:0301:0301 HLAb: 0301:0501:0201 (DR3) |
Negative | 45 | M | – | 6.2 | |
| 12 | No data | Negative | 34 | M | – | 7.7 | |
| 13 | HLAa: 1302:0102:0604 HLAb: 0101:0101:0502 |
Negative | 9 | M | – | 8.4 | |
| 14 | HLAa: 1104:0501:0301 HLAb: 0301:0501:0201 (DR3) |
Negative | 43 | F | – | 7.4 | |
| 15 | HLAa: 0401:0301:0301 (DR4) HLAb: 0401:0301:0302 (DR4) |
Negative | 10 | M | – | 8.8 | |
| Average ± SE: | 19.1 ± 3.1 | - | 7.7 ± 0.2 | ||||
| AA+ First Degree Relatives that later progressed to T1D | |||||||
| ID | Serum AA* | Age | Sex | Years to Onset | RNA RIN | ||
| 1 | HLAa: 0101:0101:0501 HLAb: 0401:0301:0302 (DR4) |
ICA512+ | 5.5 | M | 3.0 | 7.1 | |
| 2 | HLAa: 0301:0501:0201 (DR3) HLAb: 0404:0301:0302 (DR4) |
GAD65+ | 43.6 | F | 3.9 | 8.5 | |
| 3 | HLAa: 0301:0501:0201 (DR3) HLAb: 0301:0501:0201 (DR3) |
GAD65+ | 11.8 | M | 2.1 | 9.3 | |
| 4 | HLAa: 0401:0301:0302 (DR4) HLAb: 0401:0301:0302 (DR4) |
ICA+ | 23.4 | M | 1.8 | 9.2 | |
| 5 | HLAa: 0401:0301:0302 (DR4) HLAb: 0404:0301:0302 (DR4) |
GAD65+ | 40.6 | F | 3.7 | 8.8 | |
| 6 | HLAa: 0404:0301:0302 (DR4) HLAb: 0801:0401:0402 |
GAD65+ GAD65H+ | 10.0 | M | 3.3 | 9.4 | |
| 7 | HLAa: 0301:0501:0201 (DR3) HLAb: 1501:0102:0602 |
ICA512+ | 13.5 | M | 2.6 | 6.1 | |
| 8 | HLAa: 0301:0501:0201 (DR3) HLAb: 0301:0501:0201 (DR3) |
GAD65+ ICA+ | 41.7 | F | 3.0 | 7.0 | |
| 9 | HLAa: 0901:0301:0303 HLAb: 0301:0501:0201 (DR3) |
GAD65+ GAD65H+ | 50.0 | M | 1.1 | 7.2 | |
| 10 | No data | GAD65+ | 4.9 | F | 2.0 | 10 | |
| 11 | HLAa: 0401:0301:0302 (DR4) HLAb: 0801:0401:0402 |
GAD65+ ICA+ | 8.3 | M | 3.8 | 9.8 | |
| 12 | No data | GAD65+ | 12.6 | F | 3.4 | 9.7 | |
| 13 | HLAa: 0401:0301:0302 (DR4) HLAb: 0301:0501:0201(DR3) |
GAD65+ ICA+ | 11.4 | M | 2.4 | 9 | |
| 14 | HLAa: 0301:0501:0201 (DR3) HLAb: 0404:0301:0302 (DR4) |
GAD65+ ICA+ | 6.5 | M | 5.5 | 8.7 | |
| 15 | HLAa: 0301:0501:0201 (DR3) HLAb: 1302:0102:0604 |
GAD65+ | 45.5 | M | 3.1 | 8.7 | |
| 16 | HLAa: 0103:0101:0501 HLAb: 0401:0301:0302 (DR4) |
ICA512+ | 23.4 | M | 3.0 | 7.5 | |
| 17 | HLAa: 0404:0301:0302 (DR4) HLAb: 1101:0501:0301 |
GAD65+ | 41.6 | F | 3.0 | 6.9 | |
| 18 | HLAa: 0301:0501:0201 (DR3) HLAb: 0401:0301:0302 (DR4) |
GAD65+ | 8.9 | F | 2.9 | 9.1 | |
| 19 | HLAa: 0404:0301:0302 (DR4) HLAb: 0301:0501:0201 (DR3) |
GAD65+ ICA+ | 6.4 | F | 3.3 | 8.4 | |
| 20 | HLAa: 0301:0501:0201 (DR3) HLAb: 0101:0101:0501 |
GAD65+ ICA+ | 24.7 | M | 3.3 | 7.5 | |
| Average ± SE: | 21.7 ± 3.6 | 3.2±0.2 | 8.4 ± 0.2 | ||||
| T1D subjects | |||||||
| ID | Serum AA* | Age | Sex | Years after Onset | RNA RIN | ||
| 1 | HLAa: 1301:0103:0608 HLAb: 0901:0301:0303 |
GAD65+ ICA512+ mIAA+ ICA+ | 23.2 | M | 2.3 | 7.4 | |
| 2 | HLAa: 0401:0301:0302 (DR4) HLAb: 0103:0101:0501 |
GAD65+ ICA512+ mIAA+ | 23.8 | F | 2.3 | 8.4 | |
| 3 | HLAa: 0901:0301:0303 HLAb: 1201:0501:0301 |
GAD65+ mIAAA+ | 26.8 | F | 2.3 | 7.8 | |
| 4 | HLAa: 0404:0301:0302 (DR4) HLAb: 0404:0301:0302 (DR4) |
ICA512+ mIAA+ ICA+ | 13.1 | F | 2.3 | 8.5 | |
| 5 | HLAa: 0404:0301:0302 (DR4) HLAb: 0405:0301:0201 (DR4) |
GAD65+ ICA512+ mIAA+ | 40.8 | M | 2.2 | 8.6 | |
| 6 | HLAa: 0401:0301:0302 (DR4) HLAb: 0101:0101:0501 |
GAD65+ mIAA+ | 18.2 | F | 2.3 | 8.2 | |
| 7 | HLAa: 0401:0301:0302 (DR4) HLAb: 0301:0501:0201 (DR3) |
GAD65+ ICA512+ mIAA+ | 18.6 | M | 2.2 | 7.6 | |
| 8 | HLAa: 0301:0501:0201 (DR3) HLAb: 1601:0102:0502 |
GAD65+ mIAA+ | 14.7 | F | 2.2 | 7.6 | |
| 9 | HLAa: 0401:0301:0302 (DR4) HLAb: 0301:0501:0201 (DR3) |
ICA512+ mIAA+ ICA+ | 16.7 | F | 2.2 | 7.3 | |
| 10 | HLAa: 0401:0301:0302 (DR4) HLAb: 0301:0501:0201 (DR3) |
GAD65+ ICA512+ mIAA+ | 16.2 | M | 2.3 | 8.3 | |
| Average ± SE: | 20.7 ± 2.5 | 2.8 ± 0.2 | 8.2 ± 0.2 | ||||
*HLAa and HLAb, HLA Haplotype α and HLA Haplotype β shown as DRB1:DQA1:DQB1. †GAD65 - GAD65 standard (TN local) assay; Positive >0.032, ICA512 - ICA512/IA2 standard (TN local) assay; Positive >0.049, GAD65H - GAD65 harmonized assay; Positive >20, IA-2H - ICA512/IA2 harmonized assay; Positive >5, MIAA - mIAA; Positive >.01, ICA - Islet Cell Autantibody; Positive ≥10. Serum autoantibody information were provided by TrialNet.